Comparison of neuropsychological side effects between contemporary radiofrequency ablative neurosurgery for psychiatric disorders and conventional neurosurgical procedures: systematic review and meta-analysis
Background Psychiatric disorders are increasingly contributing to global disability. Despite advances in conservative management, the prevalence of treatment-resistant cases remains high. Meanwhile, neurosurgery for psychiatric disorders (NPD) remains underused, largely due to strict regulations and historical concerns, particularly those related to neuropsychological side effects (NPSE). Objective To address this issue, we conducted a systematic review with meta-analysis to compare NPSE associated with radiofrequency ablative NPD to those observed in neuro-oncological, neurovascular and epilepsy surgeries. Methods PubMed, Embase and LILACS databases were searched in April 2024 for articles published in English/Spanish from 1990 to 2022, following Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Results A total of 48 articles with 2678 participants were included. The frequency of transient and permanent NPSE in the NPD group ranged from 0.94% to 11.50% and 0.94% to 2.03%, respectively, comparable to the other surgical groups (epilepsy: 0.31–11.70%; vascular: 0.52–22.90%; oncology: 0.94–17.60% for transient NPSE; epilepsy: 0.31–12%; vascular: 0.40–1.96% and oncology: 0.84–1.48% for permanent NPSE). Regarding permanent NPSE, arguably the most critical consideration, the NPD group showed better outcomes in memory, language and social cognition than the epilepsy group, but worse outcomes in executive and perceptual-motor functions. Compared with the vascular group, the NPD group had better executive function but worse complex attention. Finally, the NPD group had fewer permanent deficits than the oncology group in executive function, complex attention and perceptual-motor domains, although language performance was lower. Conclusions Contemporary NPD apparently carries a similar risk of NPSE as other conventional neurosurgical procedures, challenging misconceptions and this unjustified barrier to its broader use.
Abstract 6496: Methylseleninic acid enhances anti-FN14 CAR-T cell effector function and redirects cytotoxicity against TGF-β-rich kidney, prostate, and brain tumors
Abstract Background: Clear cell renal cell carcinoma (ccRCC), metastatic castration-resistant prostate cancer (mCRPC), and glioblastoma (GBM) are treatment-refractory tumors marked by high TGF-β1, a master suppressor of antitumor immunity and antigen presentation. Pharmacologic methylseleninic acid (MSA) potently inhibits TGF-β1, PD-L1, and VEGF without significant off-target toxicity. FN14, the TWEAK receptor and a metastasis driver, is selectively overexpressed in these malignancies, making it a high-specificity CAR-T target. Methods: We developed second-generation anti-FN14 CARs with CD28 or 4-1BB costimulation and CD3ζ signaling and lentivirally transduced them into human CD4+/CD8+ T cells. Cytotoxicity against FN14+ ccRCC, mCRPC, GBM lines and patient-derived tumors was measured using LDH release and xCELLigence assays. Effector function was assessed by intracellular cytokines, phenotyping, and multiplex analysis. MSA was tested at physiologic concentrations to evaluate effects on CAR-T viability, metabolism, function, and tumor susceptibility. Results: Anti-FN14 CAR-T cells mediated rapid, antigen-specific lysis across all tumor types, achieving >50% specific lysis at an E:T ratio of 1:1. MSA (2.5-5 µM) reduced tumor PD-L1 and TGF-β by >40% and improved CAR-T metabolic activity, enhancing IL-2 and IFN-γ secretion. Manufacturing CAR-T cells with MSA (2.5 µM) increased cytotoxicity and persistence versus controls (p < 0.01). MSA’s effects were dose- and schedule-dependent at clinically compatible concentrations without detectable off-target toxicity. Conclusion: MSA augments anti-FN14 CAR-T cytotoxicity, metabolic fitness, and sustained effector function by suppressing tumor-derived TGF-β1 and PD-L1 and directly enhancing CAR-T activity. As a clinically relevant TGF-β1 inhibitor and active seleno-L-methionine metabolite, MSA represents a readily translatable strategy to reduce CAR-T exhaustion and improve efficacy in TGF-β-rich solid tumors. Citation Format: Gloria B. Kim, Obed B. Amissah, Casey R. Ager, Yousef Zakharia, Youcef M. Rustum. Methylseleninic acid enhances anti-FN14 CAR-T cell effector function and redirects cytotoxicity against TGF-β-rich kidney, prostate, and brain tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 6496.
Abstract 7419: Comprehensive profiling of primary and metastatic prostate tumors reveals distinct tumor and fibroblast cell states associated with androgen resistance
Abstract Prostate cancer requires continual escape from immune surveillance, but mechanisms underlying this escape in the transition from androgen sensitivity to resistance and metastasis remain incompletely understood. Androgen-deprivation therapy (ADT)—the treatment backbone—induces tumor cell apoptosis but also remodels the tumor microenvironment (TME). We have assembled a single-cell RNA-seq atlas from >800,000 cells across 68 patients treated at Columbia University and Memorial Sloan Kettering. The resource includes 33 primary tumors (16 treatment-naïve, 17 post-ADT) annotated with time to PSA recurrence, and 31 metastases, including longitudinal pre- and post-ADT data in 14 castration-sensitive tumors (CSPC), 17 castration-resistant tumors (CRPC), and 4 neuroendocrine tumors (NEPC). This dataset spans the spectrum of prostate cancer disease progression.Using ARACNe and VIPER to infer activity of transcriptional regulatory and signaling proteins, we detect conserved cell state programs while minimizing batch effects. Several significant features emerged. Immune infiltration—both lymphoid and myeloid—is significantly higher in CSPC metastases than in primary or CRPC tumors and increases further after ADT. T cells constitute ∼15% of cells in primary tumors versus 30% in treatment-naive CSPC (40% post-ADT), falling to 13% in CRPC and <1% in NEPC (p<1e-32), consistent with an initially "hot" CSPC TME that progressively excludes T cells with disease progression.Among ∼350,000 epithelial/tumor cells, trajectory analysis reveals two differentiation pathways from normal epithelium. Pathway 1—dominant in primary tumors—shows androgen receptor (AR) activity with three sub-phenotypes (T1-T3): T1 exclusive to primary tumors; T2 shared by primary and CSPC; and T3 restricted to CRPC, with high ERG expression, and very strong AR activity. Pathway 2 (clusters T4-T6), present in NEPC and a subset of CRPC, lacks AR activity and displays SOX2, FOXA2, PRKD1. These aggressive states uniformly overexpress AURKA, RET, and TOP2A, suggesting druggable targets for combination therapy.We further define five cancer-associated fibroblast (CAF) subtypes. CAF1-3 track with advanced, treatment-resistant disease—enriched in NEPC versus CRPC (25% vs 18% of CAFs) and in CRPC versus CSPC (18% vs 11%)—while CAF4-5 predominate in primary tumors. We identify druggable proteins and receptor-ligand interactions linking CAF1-3 with T4-T6 tumor states; in vivo perturbations are underway.This atlas provides a resource profiling tumor and immune ecosystems across prostate cancer progression. It highlights MR programs and stromal-tumor-immune interactions that underlie immune evasion and ADT resistance, yielding actionable targets and combination-therapy hypotheses for aggressive disease. Citation Format: Aleksandar Obradovic, Kwangmin Yoo, Chang Liu, Patrick McCann, Casey R. Ager, Matthew C. Dallos, Samir Zaidi. Comprehensive profiling of primary and metastatic prostate tumors reveals distinct tumor and fibroblast cell states associated with androgen resistance [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 7419.
Abstract 166: Rewiring the dendritic cell: Regulatory T cell axis sensitizes prostate cancer to immunotherapy.
Abstract Introduction: The prostate cancer (PCa) tumor microenvironment (TME) is immunosuppressive and resistant to immune checkpoint blockade (ICB). Based on multi-omic single cell correlatives of response to neoadjuvant Fc-enhanced (FcE) αCTLA-4 in high-risk localized PCa (NCT04301414), we explored how modulating the balance between regulatory T cells (Tregs) and dendritic cells (DCs) in the PCa TME affects sensitivity to ICB. Methods: We leveraged three single cell transcriptomic atlases of PCa to assess how Tregs and DC frequencies are dynamically regulated during PCa progression. To investigate responses to Treg depletion (via FcE-αCTLA-4) alongside DC expansion (via Flt3L-Ig) and stimulation (via STING agonist ADU-S100) in PCa, we employed the castration-sensitive MycCaP PCa model and 45-parameter spectral flow cytometry. To investigate novel direct mechanisms of DC stimulation by FcE-αCTLA-4 via Fcγ receptor (FcγR) engagement, we optimized reductionist in vitro assays involving bone marrow-derived DCs (BMDCs) from wild-type (WT) mice or mice deficient in activating FcγRs (Fcer1g-/-) or inhibitory FcγRIIb (Fcgr2b-/-). To validate this effect in vivo we established a tumor antigen-specific T cell priming assay with both flow cytometry and ex vivo 2-photon live cell imaging readouts. Results: In three independent single cell transcriptomic PCa atlases, we find cDC2 frequencies are significantly decreased in advanced PCa while effector Tregs (TNFRSF9+) increase in proportion. Hypothesizing that excessive Treg function and DC insufficiency drive ICB resistance in PCa, we find in vivo DC expansion (Flt3L-Ig) prior to hormonal therapy, Treg depletion (FcE-αCTLA-4), and in situ DC stimulation (ADU-S100) drives robust control of established MycCaP tumors, with 87% of animals tumor-free 40-days post-treatment (27/31). Using 45-parameter spectral flow cytometry we find FcE-αCTLA-4 drives DC activation prior to Treg depletion in the TME, supporting a novel direct mechanism of DC modulation by FcE-αCTLA-4. In vitro, we find cell-associated FcE-αCTLA-4 is sufficient to drive BMDC maturation in an FcγR-dependent manner. In vivo, FcE-αCTLA-4 augments DC-mediated T cell priming in an FcγR-dependent manner. Ongoing experiments are investigating how FcE-αCTLA-4 shapes DC-T cell interactions via FcγR engagement and how DC/Treg axis modulation can be optimized to improve long-term curative response rates in the MycCaP model. Conclusions: DC insufficiency and effector Treg differentiation are hallmarks of advanced PCa. Enhancing DC number and function concomitant with Treg depletion can drive effective antitumor immunity in a pre-clinical PCa model. Direct DC modulation via FcγR engagement represents a novel mechanism of response to CTLA-4-targeted ICB. These findings will inform ongoing translation of FcE-αCTLA-4 agents and development of novel immunotherapy strategies for PCa. Citation Format: Jessica C. Hill, Kade R. Copple, Collin Jugler, Phuong Nguyen, Nilika Bhattacharya, Jessica N. Lancaster, Casey R. Ager. Rewiring the dendritic cell: Regulatory T cell axis sensitizes prostate cancer to immunotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 166.
How genetic counselors in North America describe their professional identity
Abstract Professional identity is defined as the attitudes, behaviors, values, and experiences by which individuals define themselves in a professional role and is influenced by socialization during training and in the workplace. As professional identity develops and is integrated with one's personal identities, it allows an individual to think, act, and feel like a member of their chosen profession and to develop a sense of meaning, confidence, and satisfaction in their work. Conflicts may arise due to perceived differences between one's professional identity and the collective identity of the profession, resulting in stress, burnout, and attrition, all of which can negatively impact patient care and the collective identity of the genetic counseling profession. Using Social Identity Theory (SIT) as a theoretical framework to develop the semi‐structured interview protocol, recorded interviews were conducted with 50 genetic counselors who were purposefully sampled to ensure diversity of personal demographics (gender, race/ethnicity, sexual orientation, disability, and caregiver status), as well as years, settings, and roles in genetic counseling practice. Transcripts were coded and subjected to codebook thematic analysis using NVivo. Genetic counselors described their professional identity in terms of who they are (characteristics and attributes), what they do (actions and skills), and what they have (training and knowledge). The majority of participants had a multidimensional perspective of what it means to be a genetic counselor, noting the transferability of their skills to a broad set of roles and settings, which supported their sense of professional identity, particularly for those who were no longer seeing patients. Yet many expressed tension with the collective identity of the profession. Expanded opportunities for genetic counselors to work in new settings and roles require review and revision of key professional documents to ensure they are reflective of the collective identity of the genetic counseling profession.
Variants in TMEM106B and GRN , which encode lysosomal proteins, interact through unknown mechanisms to increase the risk of age-related cognitive decline and neurodegeneration. Here, we show that these variants converge on a single molecular intermediate: the cleaved intra-lysosomal fibril core of TMEM106B, a precursor to amyloid fibrils that accumulate in the aging brain. A protein-coding TMEM106B risk variant (p.T185) drives fibril core accumulation by impairing its degradation and GRN risk variants amplify this effect. Mice over-expressing the fibril core develop hallmarks of neurodegeneration, and cryo-electron tomography reveals intra-lysosomal fibrils in cultured neurons, mice, and diseased human brain. In GRN -mutation carriers, in whom fibril burden is greatest, fibrils extrude through ruptured lysosomal membranes. These findings identify intra-lysosomal TMEM106B fibrillization as a convergent neurodegeneration mechanism and potential therapeutic target.
A Retrospective Study of Long-Term Associations of Behavioral Intervention Combined with Medications in Young Children with Attention-Deficit/Hyperactivity Disorder
Objective: This study aimed to examine whether parent–child interaction therapy (PCIT), compared with other therapy modalities, was associated with differences in substance use and psychiatric outcomes in a cohort of children with attention-deficit/hyperactivity disorder (ADHD). Methods: This retrospective cohort study was conducted using medical record data from the Rochester Epidemiology Project (REP). The sample included 643 children aged ≤7 years who were diagnosed with ADHD and received either stimulant or nonstimulant medication, along with psychosocial therapy. Participants were categorized into two groups: those who documented exposure to PCIT versus other therapy modalities such as behavioral management, play therapy, cognitive behavioral therapy, parent management training, occupational therapy, speech therapy, parenting class, applied behavior analysis, and social skills training. Conditional logistic regression models were used to examine differences in baseline characteristics and outcomes between the two treatment groups. Results: Individuals in the PCIT group were more likely to have private insurance (66% vs. 57%; p = 0.016) and to fall into higher socioeconomic status quartiles ( p = 0.024) at baseline. PCIT recipients also had a higher prevalence of emotional and behavioral disturbances at baseline (40% vs. 25%; p < 0.001). The median age of the participants at follow-up was 19.6 years, indicating a median follow-up period of approximately 13 years from the initiation of treatment. At follow-up, the PCIT group demonstrated higher rates of problematic alcohol (24% vs. 17%; HR = 1.50, 95% CI: [1.02, 2.20]; p = 0.038) and cannabis use (25% vs. 18%; HR = 1.48, 95% CI: [1.03, 2.15]; p = 0.037). However, after controlling for covariates in the adjusted model, no statistically significant differences emerged between the groups across any substance use outcome. No significant differences were observed in other psychiatric diagnoses or mental health service utilization. Conclusions: Findings indicate that individuals who documented exposure to PCIT demonstrated elevated rates of alcohol and cannabis use in young adulthood, but had no other differences in psychiatric outcomes. While this aligns with prior literature reporting increased substance use risk in ADHD populations, our study cannot confirm this association relative to non-ADHD controls because such a comparison was not included. These associations likely reflect underlying differences in clinical severity and clinical comorbidities at baseline, rather than a direct effect of PCIT. Further investigation is warranted to determine the treatment effects based on baseline risk factors.
540: COMPARISON OF INITIAL SEDATION AND ANALGESIA IN PATIENTS ON BUPRENORPHINE VS OPIOID-NAIVE PATIENTS
OBJECTIVE: Accurate assessment of skin and skin changes across diverse populations is critical for patient health. To promote the knowledge and skills nurses need in practice to identify skin changes, nurse educators must include content on assessment of diverse skin tones in nursing education programs. This study’s objective was to develop and pilot education modules about the assessment of diverse skin tones to be part of an undergraduate nursing course. METHODS: In this quality improvement project, modules highlighted the importance of skin assessment and appropriate techniques for assessing erythema, pallor, cyanosis, and jaundice on diverse skin tones. Undergraduate nursing students completed a questionnaire evaluating the modules and their learning experience. RESULTS: The majority of students (≥70%) agreed or highly agreed that the modules were interesting, informative, engaging, and increased their knowledge. Comments to open-ended questions supported their evaluation ratings. CONCLUSIONS: Undergraduate nursing students positively received education modules on assessing patients with diverse skin tones. Students perceived the modules as having the potential to enhance their learning and assessment skills to prevent and detect skin changes associated with pressure injury. The modules serve as an example of a strategy to integrate education content about diverse skin tones into nursing curricula.
Dynamic investigator initiated enterprise (DIVINE) in prostate cancer: Randomized phase II trial of stereotactic body radiotherapy with or without short-course androgen deprivation and AR pathway inhibition in oligometastatic castration-sensitive prostate
TPS283 Background: Emerging evidence suggests that metastasis-directed therapy (MDT) with stereotactic body radiotherapy (SBRT) can delay systemic therapy in oligometastatic castration-sensitive prostate cancer (omCSPC). However, the optimal timing of androgen deprivation therapy (ADT) and androgen receptor pathway inhibitor (ARPI) initiation in this setting remains undefined. While deferred ADT following MDT may preserve quality of life, early short-course ADT/ARPI may eradicate micrometastatic disease and extend progression-free survival. Extracellular vesicles (EVs) carrying PSMA-positive prostate cancer (PC) signals and circulating tumor DNA (ctDNA) may serve as real-time biomarkers of MRD and treatment response. Methods: DIVINE [NCT06378866] is an open-label, phase II, randomized trial enrolling men with omCSPC defined by 1–5 metastases (≥1 extrapelvic) on conventional imaging (CT/MRI and bone scan) and testosterone >100 ng/dL. PSMA PET may be obtained for correlative purposes but does not determine eligibility. Participants (N = 220) are randomized 1:1 to: Arm A (Early systemic): SBRT plus 6 months of ADT + ARPI. Arm B (Deferred systemic): SBRT alone with observation, reserving systemic therapy until radiographic progression not amenable to further SBRT (mrPD). SBRT is delivered per institutional standard; repeat SBRT is allowed until lesions become non-addressable. The primary endpoint, modified radiographic progression-free survival (mrPFS), is the time from randomization to death or radiographic progression not amenable to further MDT, defined by PCWG3 (bone) and modified RECIST 1.1 (soft tissue) criteria on conventional imaging. Soft-tissue progression requires ≥ 20% increase in measurable disease or a new lesion; bone progression requires ≥ 2 new confirmed lesions. Secondary endpoints include OS, biochemical PFS, time to local and distant progression, and grade 3–5 adverse events during systemic therapy. Exploratory endpoints evaluate EV and ctDNA kinetics as MRD markers, correlation of PSMA-positive EV burden with outcomes, and duration of response after short-course ADT/ARPI. Correlative analyses will longitudinally quantify PSMA-positive EVs and ctDNA at baseline, on treatment, and at progression to define MRD dynamics and resistance patterns. The trial uses Pocock–Simon dynamic allocation by EV strata and metastatic burden to ensure balance across arms. The trial is open and actively enrolling across all Mayo Clinic sites; as of October 2025, 35 of the planned 220 patients have been accrued. Clinical trial information: NCT06378866 .